Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) has been given an average rating of “Buy” by the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $66.00.
A number of equities analysts have issued reports on MAZE shares. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th.
View Our Latest Report on Maze Therapeutics
Maze Therapeutics Trading Up 1.3%
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). As a group, equities analysts forecast that Maze Therapeutics will post -2.72 EPS for the current fiscal year.
Trending Headlines about Maze Therapeutics
Here are the key news stories impacting Maze Therapeutics this week:
- Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
- Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
- Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
- Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.
Insiders Place Their Bets
In other news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $27.58, for a total value of $206,850.00. Following the sale, the insider owned 26,250 shares in the company, valued at $723,975. This trade represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at $445,680.62. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 209,612 shares of company stock worth $5,734,575. Company insiders own 5.30% of the company’s stock.
Institutional Investors Weigh In On Maze Therapeutics
Several institutional investors have recently bought and sold shares of MAZE. Royal Bank of Canada increased its stake in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after acquiring an additional 931 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Maze Therapeutics by 23.0% during the third quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after acquiring an additional 977 shares during the last quarter.
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
- Five stocks we like better than Maze Therapeutics
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
